Arcutis Biotherapeutics' Zoryve Gets Health Canada Approval for Children With Atopic Dermatitis
MT Newswires Live
Aug 21
Arcutis Biotherapeutics' (ARQT) Arcutis Canada unit said Thursday that Health Canada has approved Zoryve cream 0.05% to treat mild to moderate atopic dermatitis in children 2 to 5 years old.
The approval is based on data from a phase 3 trial, which met its primary and key secondary endpoints, showing improvements in disease severity, with benefits observed as early as week 1, the company said.
Trial results were well-tolerated through week 56, with treatment-emergent adverse events predominantly mild to moderate in severity, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.